Luke Halpern, Associate Editor

In an analysis of the intention-to-treat population of the BENEFIT study, investigators demonstrated improved sustained minimal residual disease negativity with the Isa-VRd regimen in newly diagnosed multiple myeloma (NDMM).

Experts at the ASH Annual Meeting and Exposition in Orlando, Florida, explored innovative strategies and treatments for improving outcomes in diffuse large B-cell lymphoma.

The American Society of Hematology (ASH) Annual Meeting and Exposition will feature the latest news, clinical trial updates, and key opinion leaders in the hematology field.

The Advisory Committee on Immunization Practices (ACIP) voted to recommend individual-based decision-making for parents when deciding when or if to give their child the birth dose of the hepatitis B virus vaccine.

Shivang Joshi, MD, MPH, RPh, FAHS, highlights Symbravo’s non-substitutability, multi-mechanistic design, and key safety considerations for pharmacists across care settings.

Implementing a best practice advisory into physicians’ electronic health records improved lipid therapy initiation and diagnoses of hyperlipidemia and hypercholesterolemia.

Shivang Joshi, MD, MPH, RPh, FAHS, outlines essential counseling points on dosing, timing, contraindications, and rebound headache risks when dispensing Symbravo.

Pirtobrutinib’s indication was expanded for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, allowing for treatment in earlier lines of therapy.

The pneumococcal 13-valent conjugate vaccine (PCV13) was effective at preventing pneumococcal lower respiratory tract infection (LRTI) in older patients from Thailand.

A 3-month resistance exercise program helped improve walking distance, grip strength, and other parameters of physical health in patients with long COVID.

Shivang Joshi, MD, MPH, RPh, FAHS, discusses how Symbravo’s multimechanistic fixed-dose design may address gaps in acute migraine therapy for patients who do not respond to single-agent treatments.

In a phase 2 trial, the unimolecular agonist of GLP-1 and amylin induced major reductions in weight loss and hemoglobin A1c in patients with type 2 diabetes.

Examining Trends From Past Respiratory Virus Seasons Can Inform New Vaccination Strategies

Investigators determined a series of risk factors that can lead to complicated pneumococcal bacteremia, including older age and key comorbidities.

Post pandemic, invasive pneumococcal disease cases rise among youth due to declining vaccination rates, highlighting urgent public health concerns.

A more significant association with cardiovascular disease (CVD) was observed among individuals with diabetes compared with those without.

Headache specialist Shivang Joshi, MD, MPH, RPh, FAHS, explains how the dual-mechanism combination of meloxicam and rizatriptan fits into acute migraine treatment.

A recent study reveals diverse long COVID trajectories, highlighting the need for further research to understand symptoms and recovery variability.

The FDA accelerates approval of sevabertinib for advanced non–small cell lung cancer, showcasing promising efficacy and manageable safety in clinical trials.

The investigational, oral PCSK9 inhibitor has the potential to significantly reduce low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia or patients with heterozygous familial hypercholesterolemia.

The SmartPhrase listed indications for PCV20 aligned with CDC guidelines and was incorporated into provider documentation, significantly improving vaccine uptake.

Young adults with high LDL-C levels face significant gaps in statin initiation and follow-up testing, highlighting urgent needs for improved cardiovascular care.

A series of predictors were associated with a higher likelihood of intensive care unit (ICU) admission and subsequently poor outcomes in patients with Streptococcus pneumoniae bacteremia.

Hypertensive disorders of pregnancy confer increased cardiovascular risk, with heightened risk corresponding to more severe hypertension.

Heart failure prevention can be integrated into health systems to optimize care.

At 3 and 9 months, inclisiran reduced low-density lipoprotein cholesterol in patients intolerant to statins or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors at rates comparable with those in placebo-controlled trials.

Integrating a pharmacist into multidisciplinary settings allowed for more thorough low-density lipoprotein cholesterol lowering in unique settings.

A bidirectional relationship was observed between long COVID and cardiovascular disease in survey results presented at IDWeek.

New data from AHA 2025 demonstrate the benefits of pharmacist-led hypertension management in reducing hemoglobin A1c (HbA1c) and blood pressure in minority patients with type 2 diabetes.

Knowledge of serotype prevalence and virulence can optimize the management of community-acquired pneumonia.